Topics The 21st JPMA Forum" was held.
The “JPMA Forum” is held once a year with the aim of deepening understanding of the pharmaceutical industry by bringing together representatives from various sectors closely tied to the industry and representatives from member companies to engage in a frank exchange of views.In 2022, as in 2021, the event consisted solely of a lecture series; the “21st JPMA Forum” was held on November 24 at the Keidanren Hall (Chiyoda Ward, Tokyo).For this event, we invited Mr. Yoshinao Mishima, President of the Japan Agency for Medical Research and Development (AMED), to deliver a keynote address. Following opening remarks by Mr. Yasufumi Okada, Chairman of the JPMA, the keynote address was delivered as follows.
The venue
AMED's efforts to promote R&D in the health and medical fields
Mr. Yoshinao Mishima, President, Japan Agency for Medical Research and Development (AMED)
AMED has been working to promote consistent research and development in the medical field, from basic to practical application, and to put the results to practical use, as well as to improve the environment for smooth and effective research and development, aiming to "put the results to practical use and deliver them to patients and their families as soon as possible". Currently, under the second phase of the Health and Medical Care Strategy, which started in FY2020, six "integrated projects" have been defined, focusing on modalities, etc. Under the leadership of the program director (PD), projects of related ministries and agencies are coordinated and promoted in an integrated manner from basic to practical applications. In addition, PDs, Program Supervisors (PSs), and Program Officers (POs) are appointed as experts who have excellent academic experience and track records in research and development, as well as insight into the evaluation of R&D projects and business operations, in order to promote R&D in the medical field with consistent management functions. The PDs, Program Supervisors (PSs), and Program Officers (POs) are experts in the evaluation of research and development projects and business operations.
In particular, in order to promote the practical application of pharmaceuticals, it is important to conduct research and development that takes into account the characteristics and properties of the modality in collaboration with universities and industry, from the search for drug targets to clinical research. For this reason, AMED promotes fundamental research and development and regulatory science related to modalities, centered on pharmaceutical projects, to utilize innovative seeds generated in academia and other fields, and to create new drugs by utilizing technologies and knowledge related to various modalities in a cross-disease manner. In addition, we aim to create new drugs by utilizing technologies and knowledge related to various modalities in a cross-disease manner. In addition, we are working to build the necessary support infrastructure for drug discovery research and development, including the sharing of drug design technologies, compound libraries, and analytical equipment.
In addition, for the urgent issue of novel coronavirus infection (COVID-19), we have actively supported various research projects, including basic research to elucidate the pathogenesis, practical application of technologies related to diagnosis and treatment, and development of therapeutic drugs and vaccines. Based on the "Strategy for Strengthening the Vaccine Development and Production System" (approved by the Cabinet in June 2021), the measures necessary to build a system that enables rapid development and supply of vaccines include "formation of a world-class vaccine R&D center," "enhancement and acceleration of domestic and overseas clinical trials," "acceleration of the pharmaceutical approval process and improvement of standards," "drug discovery We are also working to raise the level of the drug discovery venture ecosystem. Furthermore, in March 2022, the Center for Advanced Research and Development Strategies (SCARDA) will be established within the AMED to engage in strategic funding of research expenses, and has already adopted issues such as corona vaccines with a view to the next pandemic.
Scene of the lecture
( Tokio Iguchi, Executive Director)